Lakefront Biotherapeutics NV
GXE
Company Profile
Business description
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
Contact
Schalienhoevedreef 20 T
Mechelen2800
BELT: +32 15342900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
452
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.70 | 60.30 | 0.69% |
| CAC 40 | 7,884.03 | 48.72 | 0.62% |
| DAX 40 | 25,230.93 | 291.58 | 1.17% |
| Dow JONES (US) | 50,926.56 | 20.51 | 0.04% |
| FTSE 100 | 10,463.24 | 34.97 | 0.34% |
| HKSE | 23,972.29 | 640.98 | -2.60% |
| NASDAQ | 26,871.60 | 10.53 | 0.04% |
| Nikkei 225 | 68,309.46 | 647.26 | -0.94% |
| NZX 50 Index | 13,680.49 | 130.02 | -0.94% |
| S&P 500 | 7,666.45 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,682.10 | 67.70 | 0.79% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |